EBCC 2014 Satellite Symposium supported by GSK: 'Heading in the right direction? Optimal sequencing pathways for HER2-positive metastatic breast cancer'

Prof Azim talks through the latest options available for HER2-positive breast cancer.

To view the slides fullscreen click the square and arrows button at the bottom right of the player

GSK has paid for the organisational costs of the symposium, and honoraria for the chairperson and speakers. GSK has contributed to the agenda and content of this meeting.